CTDNA
Clinical trials for CTDNA explained in plain language.
Never miss a new study
Get alerted when new CTDNA trials appear
Sign up with your email to follow new studies for CTDNA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
DNA blood test may personalize esophageal cancer therapy
Disease control Recruiting nowThis study looks at whether tracking tumor DNA in the blood (ctDNA) can help doctors decide the best treatment for people with advanced esophageal cancer. About 30 participants will receive a combination of immunotherapy and chemotherapy, followed by radiation and chemo. The goal…
Matched conditions: CTDNA
Phase: NA • Sponsor: The Central Hospital of Lishui City • Aim: Disease control
Last updated May 26, 2026 06:36 UTC
-
New combo aims to wipe out hidden cancer cells after chemo
Disease control Recruiting nowThis study tests whether two drugs, fruquintinib and tislelizumab, can control colorectal cancer in people who still have signs of cancer cells in their blood after finishing chemotherapy. About 20 adults with stable disease will receive the combination to see if it is safe and c…
Matched conditions: CTDNA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 06:34 UTC
-
Blood test may tailor chemo duration for colorectal cancer patients
Disease control Recruiting nowThis study tests whether a blood test that detects tumor DNA can help doctors decide how long chemotherapy should last for people with certain types of colorectal cancer. About 340 adults with stage II or low-risk stage III colorectal cancer will be randomly assigned to standard …
Matched conditions: CTDNA
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 26, 2026 06:22 UTC
-
New blood test could personalize chemo for colon cancer patients
Disease control Recruiting nowThis study tests whether a blood test that detects cancer DNA can help doctors decide on the best chemotherapy for people with high-risk stage II colorectal cancer. About 340 patients who still have cancer DNA in their blood one month after surgery will receive different chemothe…
Matched conditions: CTDNA
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
Blood test may personalize chemo for aggressive colon cancer
Disease control Recruiting nowThis study is for people with high-risk stage III colorectal cancer. It uses a blood test (ctDNA) to see if adding a targeted drug (bevacizumab) to standard chemotherapy works better than chemo alone. About 100 participants will be randomly assigned to one of two treatment groups…
Matched conditions: CTDNA
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
Blood test could personalize chemo for early colorectal cancer patients
Disease control Recruiting nowThis study looks at whether a blood test that detects tumor DNA (ctDNA) can help doctors decide on the best chemotherapy for people with stage I or low-risk stage II colorectal cancer after surgery. About 80 participants who test positive for ctDNA one month after surgery will re…
Matched conditions: CTDNA
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 18, 2026 12:01 UTC
-
Blood test breakthrough could catch deadly bile duct cancers early
Diagnosis Recruiting nowThis study is testing a new blood test that looks for DNA changes from tumors to detect biliary tract cancers (cancers of the bile ducts and gallbladder). These cancers are often found late and have a low survival rate. The test aims to find them earlier and help doctors monitor …
Matched conditions: CTDNA
Sponsor: Yingbin Liu, MD, PhD, FACS • Aim: Diagnosis
Last updated May 20, 2026 11:56 UTC
-
Blood test may help doctors choose better cancer treatment
Knowledge-focused Recruiting nowThis study looks at whether a simple blood test that tracks tumor DNA (ctDNA) can help doctors decide the best treatment for people with HER2-negative metastatic breast cancer. About 122 participants will first receive antibody-drug conjugate (ADC) therapy, and then based on how …
Matched conditions: CTDNA
Phase: PHASE2 • Sponsor: Fudan University • Aim: Knowledge-focused
Last updated May 22, 2026 13:50 UTC